Seegene (KOSDAQ:A096530) - Stock Price, News & Analysis

A096530 Stock Overview

Manufactures and sells molecular diagnostics products worldwide. More details

A096530 fundamental analysis
Snowflake Score
Valuation	1/6
Future Growth	4/6
Past Performance	1/6
Financial Health	4/6
Dividends	2/6

Rewards

Earnings are forecast to grow 35.21% per year

Became profitable this year

Risk Analysis

Large one-off items impacting financial results

Dividend of 3.47% is not well covered by earnings

Seegene, Inc. Competitors

BioNote

KOSE:A377740

₩469.5b

Medy-Tox

KOSDAQ:A086900

₩867.0b

PharmaResearch

KOSDAQ:A214450

₩2.1t

BNC Korea

KOSDAQ:A256840

₩275.4b

Price History & Performance

Summary of all time highs, changes and price drops for Seegene
Historical stock prices
Current Share Price	₩23,050.00
52 Week High	₩35,950.00
52 Week Low	₩19,500.00
Beta	-1.14
11 Month Change	-0.86%
3 Month Change	-13.51%
1 Year Change	7.46%
33 Year Change	-67.94%
5 Year Change	63.77%
Change since IPO	447.94%

Investors Shouldn't Be Too Comfortable With Seegene's (KOSDAQ:096530) Earnings

Nov 22

Is Seegene (KOSDAQ:096530) Using Too Much Debt?

Nov 12

Recent updates

Investors Shouldn't Be Too Comfortable With Seegene's (KOSDAQ:096530) Earnings

Nov 22

Is Seegene (KOSDAQ:096530) Using Too Much Debt?

Nov 12

Seegene, Inc.'s (KOSDAQ:096530) Share Price Boosted 44% But Its Business Prospects Need A Lift Too

Aug 10

A Look At The Fair Value Of Seegene, Inc. (KOSDAQ:096530)

Mar 07

Is Seegene, Inc. (KOSDAQ:096530) Trading At A 32% Discount?

May 06

I Ran A Stock Scan For Earnings Growth And Seegene (KOSDAQ:096530) Passed With Ease

Mar 15

Declining Stock and Solid Fundamentals: Is The Market Wrong About Seegene, Inc. (KOSDAQ:096530)?

Dec 23

Can You Imagine How Elated Seegene's (KOSDAQ:096530) Shareholders Feel About Its 656% Share Price Gain?

Dec 08

I Ran A Stock Scan For Earnings Growth And Seegene (KOSDAQ:096530) Passed With Ease

Nov 24

Shareholder Returns

	A096530	KR Biotechs	KR Market
7D	4.5%	-8.1%	2.9%
1Y	7.5%	18.1%	-2.8%

Return vs Industry: A096530 underperformed the KR Biotechs industry which returned 18.1% over the past year.

Return vs Market: A096530 exceeded the KR Market which returned -2.8% over the past year.

Price Volatility

Is A096530's price volatile compared to industry and market?
A096530 volatility
A096530 Average Weekly Movement	5.1%
Biotechs Industry Average Movement	8.1%
Market Average Movement	5.6%
10% most volatile stocks in KR Market	11.6%
10% least volatile stocks in KR Market	2.7%

Stable Share Price: A096530 has not had significant price volatility in the past 3 months compared to the KR market.

Volatility Over Time: A096530's weekly volatility (5%) has been stable over the past year.

About the Company

Founded	Employees	CEO	Website
2000	n/a	Jong-Yoon Chun	www.seegene.com

Seegene, Inc. manufactures and sells molecular diagnostics products worldwide. It offers IVD products comprising respiratory disease detection products for respiratory infections; gastrointestinal disease detection products for gastrointestinal tract infections; human papillomavirus detection products; sexually transmitted infections causative pathogens detection products; tuberculosis detection products; drug resistance products; Magicplex sepsis real-time test for the detection and identification of sepsis causing pathogens; and meningitis detection products. The company also provides other products for the detection of SNPs in factor II, factor V, and MTHFR genes.

Seegene, Inc. Fundamentals Summary

How do Seegene's earnings and revenue compare to its market cap?
A096530 fundamental statistics
Market cap	₩1.07t
Earnings (TTM)	₩29.47b
Revenue (TTM)	₩399.42b

36.1x

P/E Ratio

2.7x

P/S Ratio

Is A096530 overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
A096530 income statement (TTM)
Revenue	₩399.42b
Cost of Revenue	₩153.82b
Gross Profit	₩245.60b
Other Expenses	₩216.13b
Earnings	₩29.47b

Last Reported Earnings

Sep 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)	637.76
Gross Margin	61.49%
Net Profit Margin	7.38%
Debt/Equity Ratio	7.4%

How did A096530 perform over the long term?

See historical performance and comparison

Dividends

3.5%

Current Dividend Yield

126%

Payout Ratio

Does A096530 pay a reliable dividends?

See A096530 dividend history and benchmarks

When do you need to buy A096530 by to receive an upcoming dividend?
Seegene dividend dates
Ex Dividend Date	Sep 27 2024
Dividend Pay Date	Nov 26 2024
Days until Ex dividend	58 days
Days until Dividend pay date	2 days

Does A096530 pay a reliable dividends?

See A096530 dividend history and benchmarks

A096530 Stock Overview

Rewards

Risk Analysis

Seegene, Inc. Competitors

KOSE:A377740

₩469.5b

KOSDAQ:A086900

₩867.0b

KOSDAQ:A214450

₩2.1t

KOSDAQ:A256840

₩275.4b

Price History & Performance

Recent News & Updates

Investors Shouldn't Be Too Comfortable With Seegene's (KOSDAQ:096530) Earnings

Third quarter 2024 earnings released: EPS: ₩36.00 (vs ₩101 loss in 3Q 2023)

Is Seegene (KOSDAQ:096530) Using Too Much Debt?

Seegene, Inc.(KOSDAQ:A096530) dropped from FTSE All-World Index (USD)

Upcoming dividend of ₩200 per share

Investor sentiment deteriorates as stock falls 16%

Recent updates

Investors Shouldn't Be Too Comfortable With Seegene's (KOSDAQ:096530) Earnings

Third quarter 2024 earnings released: EPS: ₩36.00 (vs ₩101 loss in 3Q 2023)

Is Seegene (KOSDAQ:096530) Using Too Much Debt?

Seegene, Inc.(KOSDAQ:A096530) dropped from FTSE All-World Index (USD)

Upcoming dividend of ₩200 per share

Investor sentiment deteriorates as stock falls 16%

Seegene, Inc. Develops mpox PCR Test Assays following the WHO Global Health Emergency Declaration

New minor risk - Share price stability

Seegene, Inc.'s (KOSDAQ:096530) Share Price Boosted 44% But Its Business Prospects Need A Lift Too

Now 28% overvalued after recent price rise

Upcoming dividend of ₩200 per share

Now 20% overvalued

Upcoming dividend of ₩200 per share

Full year 2023 earnings: EPS and revenues exceed analyst expectations

A Look At The Fair Value Of Seegene, Inc. (KOSDAQ:096530)

New minor risk - Share price stability

Now 28% overvalued after recent price rise

Upcoming dividend of ₩200 per share at 3.5% yield

Price target decreased by 8.8% to ₩25,000

New minor risk - Share price stability

Upcoming dividend of ₩200 per share at 3.7% yield

Consensus EPS estimates fall from profit to ₩18.00 loss

New minor risk - Share price stability

Investor sentiment improves as stock rises 18%

Seegene Inc. Unveils Solutions to Popularize Molecular Diagnostics At 2023 AACC

Seegene, Inc. (KOSDAQ:A096530) announces an Equity Buyback for KRW 30,000 million worth of its shares.

Upcoming dividend of ₩200 per share at 3.7% yield

Upcoming dividend of ₩200 per share at 3.1% yield

Full year 2022 earnings: EPS and revenues miss analyst expectations

Consensus revenue estimates fall by 21%

Upcoming dividend of ₩400 per share

Investor sentiment deteriorated over the past week

Price target decreased to ₩38,667

Less than half of directors are independent

Seegene, Inc. (KOSDAQ:A096530) announces an Equity Buyback for KRW 50,000 million worth of its shares.

Upcoming dividend of ₩200 per share

Consensus revenue estimates fall by 24%

Now 20% undervalued

Investor sentiment improved over the past week

Seegene, Inc. to Pave Way for PCR Testing At Local Clinics with EU-Approved Multiplex Test and Fully Automated PCR Solution

Seegene Inc. Develops PCR Test to Detect Monkeypox Virus

Upcoming dividend of ₩400 per share

Now 24% undervalued after recent price drop

Price target decreased to ₩71,500

Seegene, Inc. Unveils World's First Commercialized '3 Ct' PCR Assay

Less than half of directors are independent

Investor sentiment deteriorated over the past week

Now 21% undervalued after recent price drop

Seegene's Allplex™ RV Master Assay Receives Australian TGA Approval

Full year 2021 earnings: EPS and revenues miss analyst expectations

Seegene Inc. Unveils New Assay Optimized for On-Site Testing in 'Living with Covid-19' Era

Consensus revenue estimates increase by 13%

Consensus revenue estimates increase by 10%

Investor sentiment improved over the past week

Seegene Inc. to Launch New COVID-19 PCR Test with a Reduced Turnaround Time Optimized for Mass Testing

Seegene Inc. Announces Allplex Sars Cov-2 FluA/FluB/RSV Assay Approved Under Health Canada's Interim Order

Seegene Inc. Unveils Another Series of Diagnostic Test that Detects the Ever-Changing COVID-19 Variant Landscape

Seegene's High Multiplex Pcr Assay Capable of Detecting New Omicron Variant

Investor sentiment improved over the past week